LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 237

Search options

  1. Book ; Online: Radioimmunotherapy - Translational Opportunities and Challenges

    Gaipl, Udo S. / Multhoff, Gabriele / Graham Pockley, Alan / Rödel, Franz / Rödel, Franz

    2020  

    Keywords Medicine ; Oncology ; translational reseach ; Immunotherapy ; Radiotherapy ; translational radioimmunotherapy ; Radioimmunotherapy
    Size 1 electronic resource (144 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021230530
    ISBN 9782889636150 ; 2889636151
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article ; Online: Future prospects in radiation oncology from the perspective of innovative radiation biology.

    Rödel, Franz / Gaipl, Udo

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al

    2023  Volume 199, Issue 12, Page(s) 1077–1079

    MeSH term(s) Humans ; Radiation Oncology/education ; Radiobiology ; Curriculum
    Language English
    Publishing date 2023-11-24
    Publishing country Germany
    Document type Editorial
    ZDB-ID 84983-2
    ISSN 1439-099X ; 0179-7158 ; 0039-2073
    ISSN (online) 1439-099X
    ISSN 0179-7158 ; 0039-2073
    DOI 10.1007/s00066-023-02163-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Thesis: Funktionelle und molekulare Untersuchungen zur entzündungsmodulierenden Wirkung ionisierender Strahlung

    Rödel, Franz

    die Bedeutung des transforming growth factor beta 1

    2004  

    Author's details vorgelegt von Franz Rödel
    Language German ; English
    Size getr. Zählung : Ill., graph. Darst.
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Erlangen, Nürnberg, Habil.-Schr., 2004
    Note Enth. Beitr. in engl. Sprache
    HBZ-ID HT014487239
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Book ; Thesis: Suppression von TNFalpha durch Yersinia-Outer-Protein B

    Rödel, Franz

    ein neuer Pathogenitätsmechanismus in der akuten Yersiniose

    1995  

    Author's details vorgelegt von Franz Rödel
    Language German
    Size 87 S. : Ill., graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Erlangen-Nürnberg, Univ., Diss., 1995
    HBZ-ID HT006879796
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  5. Book ; Online ; Thesis: Prospektive Untersuchung tumorassoziierter und immunonkologisch relevanter miRNA im Verlauf der Strahlentherapie von Patienten mit nicht-kleinzelligem Bronchialkarzinom (NSCLC)

    Kadler, Frauke [Verfasser] / Schütte, Wolfgang [Gutachter] / Rödel, Franz [Gutachter]

    2023  

    Author's details Frauke Kadler ; Gutachter: Wolfgang Schütte, Franz Rödel
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universitäts- und Landesbibliothek Sachsen-Anhalt
    Publishing place Halle (Saale)
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  6. Article: Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer-A Promising Signaling Network for Therapeutic Interventions.

    Güllülü, Ömer / Hehlgans, Stephanie / Rödel, Claus / Fokas, Emmanouil / Rödel, Franz

    Cancers

    2021  Volume 13, Issue 4

    Abstract: Despite recent advances in the treatment of colorectal cancer (CRC), patient's individual response and clinical follow-up vary considerably with tumor intrinsic factors to contribute to an enhanced malignancy and therapy resistance. Among these markers, ... ...

    Abstract Despite recent advances in the treatment of colorectal cancer (CRC), patient's individual response and clinical follow-up vary considerably with tumor intrinsic factors to contribute to an enhanced malignancy and therapy resistance. Among these markers, upregulation of members of the inhibitor of apoptosis protein (IAP) family effects on tumorigenesis and radiation- and chemo-resistance by multiple pathways, covering a hampered induction of apoptosis/autophagy, regulation of cell cycle progression and DNA damage response. These mechanisms are tightly controlled by the tumor suppressor p53 and thus transcriptional and post-translational regulation of IAPs by p53 is expected to occur in malignant cells. By this, cellular IAP1/2, X-linked IAP, Survivin, BRUCE and LIVIN expression/activity, as well as their intracellular localization is controlled by p53 in a direct or indirect manner via modulating a multitude of mechanisms. These cover, among others, transcriptional repression and the signal transducer and activator of transcription (STAT)3 pathway. In addition, p53 mutations contribute to deregulated IAP expression and resistance to therapy. This review aims at highlighting the mechanistic and clinical importance of IAP regulation by p53 in CRC and describing potential therapeutic strategies based on this interrelationship.
    Language English
    Publishing date 2021-02-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13040624
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Advances in nanotechnology-based platforms for survivin-targeted drug discovery.

    George, Rosemol / Hehlgans, Stephanie / Fleischmann, Maximillian / Rödel, Claus / Fokas, Emmanouil / Rödel, Franz

    Expert opinion on drug discovery

    2022  Volume 17, Issue 7, Page(s) 733–754

    Abstract: Introduction: Due to its unique functional impact on multiple cancer cell circuits including proliferation, apoptosis, tumor dissemination, DNA damage repair, and immune response, the inhibitor of apoptosis protein (IAP) survivin has gained high ... ...

    Abstract Introduction: Due to its unique functional impact on multiple cancer cell circuits including proliferation, apoptosis, tumor dissemination, DNA damage repair, and immune response, the inhibitor of apoptosis protein (IAP) survivin has gained high interest as a molecular target and a multitude of therapeutics were developed to interfere with survivin expression and functionality. First clinical evaluations of these therapeutics, however, were disappointing highlighting the need to develop advanced delivery systems of survivin-targeting therapeutics.
    Areas covered: This review focuses on advancements in nanocarriers to molecularly target survivin in human malignancies. A plethora of nanoparticle platforms, including liposomes, polymeric systems, dendrimers, inorganic nanocarriers, RNA/DNA nanotechnology and exosomes, are discussed in the background of survivin-tailored RNA interference, small molecule inhibitors, dominant negative mutants or survivin vaccination or combined modality treatment with chemotherapeutic drugs and photo-dynamic/photothermal strategies.
    Expert opinion: Novel therapeutic approaches include the use of biocompatible nanoformulations carrying gene silencing or drug molecules to directly or indirectly target proteins, allow for a more precise and controlled delivery of survivin therapeutics. Moreover, surface modification of these nanocarriers may result in a tumor entity-specific delivery. Therefore, nanomedicine exploiting survivin-tailored strategies in a multimodal background is considered the way forward to enhance the development of future personalized medicine.
    MeSH term(s) Drug Delivery Systems ; Drug Discovery ; Humans ; Nanomedicine ; Nanoparticles ; Nanotechnology ; Neoplasms/pathology ; Survivin/therapeutic use
    Chemical Substances Survivin
    Language English
    Publishing date 2022-05-23
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1080/17460441.2022.2077329
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.

    Viktorsson, Kristina / Rieckmann, Thorsten / Fleischmann, Maximilian / Diefenhardt, Markus / Hehlgans, Stephanie / Rödel, Franz

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al

    2023  Volume 199, Issue 12, Page(s) 1091–1109

    Abstract: Recent advances in understanding the tumor's biology in line with a constantly growing number of innovative technologies have prompted characterization of patients' individual malignancies and may display a prerequisite to treat cancer at its patient ... ...

    Abstract Recent advances in understanding the tumor's biology in line with a constantly growing number of innovative technologies have prompted characterization of patients' individual malignancies and may display a prerequisite to treat cancer at its patient individual tumor vulnerability. In recent decades, radiation- induced signaling and tumor promoting local events for radiation sensitization were explored in detail, resulting the development of novel molecular targets. A multitude of pharmacological, genetic, and immunological principles, including small molecule- and antibody-based targeted strategies, have been developed that are suitable for combined concepts with radiation (RT) or chemoradiation therapy (CRT). Despite a plethora of promising experimental and preclinical findings, however, so far, only a very limited number of clinical trials have demonstrated a better outcome and/or patient benefit when RT or CRT are combined with targeted agents. The current review aims to summarize recent progress in molecular therapies targeting oncogenic drivers, DNA damage and cell cycle response, apoptosis signaling pathways, cell adhesion molecules, hypoxia, and the tumor microenvironment to impact therapy refractoriness and to boost radiation response. In addition, we will discuss recent advances in nanotechnology, e.g., RNA technologies and protein-degrading proteolysis-targeting chimeras (PROTACs) that may open new and innovative ways to benefit from molecular-targeted therapy approaches with improved efficacy.
    MeSH term(s) Humans ; Molecular Targeted Therapy ; Neoplasms/radiotherapy ; Neoplasms/drug therapy ; Antineoplastic Agents/therapeutic use ; Signal Transduction ; Tumor Microenvironment
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2023-04-11
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 84983-2
    ISSN 1439-099X ; 0179-7158 ; 0039-2073
    ISSN (online) 1439-099X
    ISSN 0179-7158 ; 0039-2073
    DOI 10.1007/s00066-023-02064-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.

    Fleischmann, Maximilian / Diefenhardt, Markus / Nicolas, Adele M / Rödel, Franz / Ghadimi, Michael / Hofheinz, Ralf-Dieter / Greten, Florian R / Rödel, Claus / Fokas, Emmanouil

    Clinical and translational radiation oncology

    2022  Volume 34, Page(s) 99–106

    Abstract: Purpose: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and ... ...

    Abstract Purpose: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and survival, remains a major challenge. Our group has recently unraveled a critical role of interleukin-1α (IL-1α) signaling in activating inflammatory cancer-associated fibroblasts (iCAFs) and mediating radiation-induced senescence, extracellular matrix (ECM) accumulation, and ultimately therapy resistance. We here summarize the recently initiated ACO/ARO/AIO-21 phase I trial, testing the IL-1 receptor antagonist (IL-1 RA) anakinra in combination with fluoropyrimidine-based chemoradiotherapy (CRT) for advanced rectal cancer.
    Methods/design: The ACO/ARO/AIO-21 is an investigator-driven, prospective, open-labeled phase I drug-repurposing trial assessing the maximum tolerated dose (MTD) of capecitabine administered concurrently to standard preoperative radiotherapy (45 Gy in 25 fractions followed by 9 Gy boost in 5 fractions) in combination with fixed doses of the IL1-RA anakinra (100 mg, days -10 to 30). Capecitabine will be administered using a 3 + 3 dose-escalation design (500 mg/m
    Discussion: Based on extensive preclinical research, the ACO/ARO/AIO-21 phase I trial will assess whether the IL-1RA anakinra can be safely combined with fluoropyrimidine-based CRT in rectal cancer. It will further explore the potential of IL-1 inhibition to overcome therapy resistance and improve response rates. A comprehensive translational research program will expand our understanding from a clinical perspective and may help translate the results into a randomized phase II trial.
    Language English
    Publishing date 2022-04-06
    Publishing country Ireland
    Document type Journal Article
    ISSN 2405-6308
    ISSN (online) 2405-6308
    DOI 10.1016/j.ctro.2022.04.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Image-guided radiotherapy in an orthotopic mouse model of rectal cancer.

    Nicolas, Adele M / Pesic, Marina / Rödel, Franz / Fokas, Emmanouil / Greten, Florian R

    STAR protocols

    2022  Volume 3, Issue 4, Page(s) 101749

    Abstract: Radiobiology research in rectal cancer has been limited to cell lines, patient-derived organoids (PDOs), or xenografts. Here, we describe a protocol which recapitulates more efficiently the complex contributions of the tumor microenvironment. This ... ...

    Abstract Radiobiology research in rectal cancer has been limited to cell lines, patient-derived organoids (PDOs), or xenografts. Here, we describe a protocol which recapitulates more efficiently the complex contributions of the tumor microenvironment. This approach establishes a preclinical mouse model of rectal cancer by intrarectal transplantation of genetically modified organoids into immunocompetent mice followed by precise image-guided radiotherapy (IGRT) of organoid-induced tumors. This model represents a useful platform to study the cellular and molecular determinants of therapy resistance in rectal cancer. For complete details on the use and execution of this protocol, please refer to Nicolas et al. (2022).
    MeSH term(s) Humans ; Mice ; Animals ; Radiotherapy, Image-Guided/methods ; Rectal Neoplasms ; Disease Models, Animal ; Heterografts ; Tumor Microenvironment
    Language English
    Publishing date 2022-10-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2666-1667
    ISSN (online) 2666-1667
    DOI 10.1016/j.xpro.2022.101749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top